Iron Uptake Mediated by Binding of H-Ferritin to the TIM-2 Receptor in Mouse Cells

Department of Biology, North Carolina Agricultural and Technical State University, Greensboro, North Carolina, United States of America.
PLoS ONE (Impact Factor: 3.23). 08/2011; 6(8):e23800. DOI: 10.1371/journal.pone.0023800
Source: PubMed


Ferritin binds specifically and saturably to a variety of cell types, and recently several ferritin receptors have been cloned. TIM-2 is a specific receptor for H ferritin (HFt) in the mouse. TIM-2 is a member of the T cell immunoglobulin and mucin domain containing (TIM) protein family and plays an important role in immunity. The expression of TIM-2 outside of the immune system indicates that this receptor may have broader roles. We tested whether ferritin binding to TIM-2 can serve as an iron delivery mechanism. TIM-2 was transfected into normal (TCMK-1) mouse kidney cells, where it was appropriately expressed on the cell surface. HFt was labeled with (55)Fe and (55)Fe-HFt was incubated with TIM-2 positive cells or controls. (55)Fe-HFt uptake was observed only in TIM-2 positive cells. HFt uptake was also seen in A20 B cells, which express endogenous TIM-2. TIM-2 levels were not increased by iron chelation. Uptake of (55)Fe-HFt was specific and temperature-dependent. HFt taken up by TIM-2 positive cells transited through the endosome and eventually entered a lysosomal compartment, distinguishing the HFt pathway from that of transferrin, the classical vehicle for cellular iron delivery. Iron delivered following binding of HFt to TIM-2 entered the cytosol and became metabolically available, resulting in increased levels of endogenous intracellular ferritin. We conclude that TIM-2 can function as an iron uptake pathway.

Download full-text


Available from: Wei Wang,
    • "iron-requiring cells (Chua et al., 2007). Ferritins are ubiquitously expressed proteins, which are involved in the sequestration and storage of iron (Han et al., 2011). Intracellular iron level regulates the abundance and availability of TFR and the intensity of ferritin protein post transcriptionally through iron regulatory proteins. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Recently, we have described the use of Caerulomycin A (CaeA) as a potent novel immunosuppressive agent. Immunosuppressive drugs are crucial for long-term graft survival following organ transplantation and treatment of autoimmune diseases, inflammatory disorders, hypersensitivity to allergens, etc. The objective of this study was to identify cellular target of CaeA and decipher its mechanism of action. Jurkat cells were treated with CaeA and cellular iron content, iron uptake/release, DNA content and dNTP pool determined. Activation of MAPKs; expression level of TFR1, ferritin and cell cycle control molecules; ROS level and cell viability were measured using Western blotting, qRT-PCR or flow cytometry. CaeA causes intracellular iron depletion by reduced uptake and increased release by cells. CaeA causes cell cycle arrest by (i) inhibiting ribonucleotide reductase (RNR) enzyme, which catalyses the rate-limiting step in the synthesis of DNA (ii) stimulating MAPKs signalling transduction pathways that play important role in cell growth, proliferation and differentiation and (iii) by targeting cell cycle control molecules such as cyclin D1, cdk4 and p21(CIP1/WAF1) . The effect of CaeA on cell proliferation is reversible. CaeA exerts its immunosuppressive effect by targeting iron. The effect is reversible which makes CaeA not only an attractive candidate for development as potent immunosuppressive drug, but also indicate that iron chelation can be used as a rationale approach to selectively suppress the immune system; because compared to normal cells, rapidly proliferating cells require higher utilization of iron. This article is protected by copyright. All rights reserved.
    British Journal of Pharmacology 12/2014; 172(9). DOI:10.1111/bph.13051 · 4.84 Impact Factor
  • Source
    • "Studies have shown that extracellular ferritin can function as an iron carrier to provide iron to cells (28,29). Ferritin receptors are presented on lymphocytes and on some other cell types, but their physiological functions have not been fully defined (30). The plasma ferritin concentration is used as useful indicator of iron stores (31). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Iron metabolism has been intensively examined over the last decade and there are many new players in this field which are worth to be introduced. Since its discovery many studies confirmed role of liver hormone hepcidin as key regulator of iron metabolism and pointed out liver as the central organ of system iron homeostasis. Liver cells receive multiple signals related to iron balance and respond by transcriptional regulation of hepcidin expression. This liver hormone is negative regulator of iron metabolism that represses iron efflux from macrophages, hepatocytes and enterocytes by its binding to iron export protein ferroportin. Ferroportin degradation leads to cellular iron retention and decreased iron availability. At level of a cell IRE/IRP (iron responsive elements/iron responsive proteins) system allows tight regulation of iron assimilation that prevents an excess of free intracellular iron which could lead to oxidative stress and damage of DNA, proteins and lipid membranes by ROS (reactive oxygen species). At the same time IRE/IRP system provides sufficient iron in order to meet the metabolic needs. Recently a significant progress in understanding of iron metabolism has been made and new molecular participants have been characterized. Article gives an overview of the current understanding of iron metabolism: absorption, distribution, cellular uptake, release, and storage. We also discuss mechanisms underlying systemic and cellular iron regulation with emphasis on central regulatory hormone hepcidin.
    Biochemia Medica 10/2012; 22(3):311-28. DOI:10.11613/BM.2012.034 · 2.67 Impact Factor
  • Source
    • "The uptake of H-ferritin results in an increase in the labile pool of iron within oligodendrocytes, which in turn causes a decrease in IRP/IRE binding and presumably decreased transferrin receptor expression, while the expression of the Hferritin receptor in rodents is thought to be independent of IRE/IRP control (Hulet et al. 2000). The receptor for H-ferritin on rat oligodendrocytes is T cell immunoglobulin and mucin domain-containing protein-2 (Tim-2) (Todorich et al. 2008), and indeed, no standard IRE was found for Tim-2 (Han et al. 2011). However, Tim-2 is not expressed in humans (Kuchroo et al. 2003). "
    [Show abstract] [Hide abstract]
    ABSTRACT: J. Neurochem. (2012) 120, 7–25. Iron, an essential element used for a multitude of biochemical reactions, abnormally accumulates in the CNS of patients with multiple sclerosis (MS). The mechanisms of abnormal iron deposition in MS are not fully understood, nor do we know whether these deposits have adverse consequences, that is, contribute to pathogenesis. With some exceptions, excess levels of iron are represented concomitantly in multiple deep gray matter structures often with bilateral representation, whereas in white matter, pathological iron deposits are usually located at sites of inflammation that are associated with veins. These distinct spatial patterns suggest disparate mechanisms of iron accumulation between these regions. Iron has been postulated to promote disease activity in MS by various means: (i) iron can amplify the activated state of microglia resulting in the increased production of proinflammatory mediators; (ii) excess intracellular iron deposits could promote mitochondria dysfunction; and (iii) improperly managed iron could catalyze the production of damaging reactive oxygen species (ROS). The pathological consequences of abnormal iron deposits may be dependent on the affected brain region and/or accumulation process. Here, we review putative mechanisms of enhanced iron uptake in MS and address the likely roles of iron in the pathogenesis of this disease.
    Journal of Neurochemistry 01/2012; 120(1):7-25. DOI:10.1111/j.1471-4159.2011.07536.x · 4.28 Impact Factor
Show more